Tamgiblimab Biosimilar – Anti-TIGIT mAb – Research Grade

Introduction

Tamgiblimab Biosimilar, also known as Anti-TIGIT mAb, is a novel monoclonal antibody designed to target and inhibit the T cell immunoglobulin and ITIM domain (TIGIT) protein. This protein is a co-inhibitory receptor expressed on various immune cells, including T cells, NK cells, and dendritic cells, and plays a critical role in regulating immune responses. Tamgiblimab Biosimilar has been developed as a potential therapeutic agent for the treatment of various diseases, including cancer and autoimmune disorders.

Structure of Tamgiblimab Biosimilar

Tamgiblimab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, composed of two identical heavy chains and two identical light chains. The heavy chain consists of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chain contains one constant domain (CL) and one variable domain (VL). The variable domains of both heavy and light chains are responsible for binding to the TIGIT protein.

Mechanism of Action

Tamgiblimab Biosimilar exerts its therapeutic effect by binding to the TIGIT protein on immune cells. This binding prevents the interaction of TIGIT with its ligands, CD155 and CD112, which are expressed on antigen-presenting cells and tumor cells. This interaction between TIGIT and its ligands leads to the inhibition of T cell activation and proliferation, resulting in the suppression of immune responses. By blocking this interaction, Tamgiblimab Biosimilar enhances T cell function and promotes anti-tumor immune responses.

Applications of Tamgiblimab Biosimilar

Tamgiblimab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various diseases. The primary focus of these trials is on its potential as an anti- cancer therapy. TIGIT has been found to be overexpressed in various types of cancer, including lung, breast, and ovarian cancer, and has been associated with poor prognosis. Tamgiblimab Biosimilar has shown to have anti-tumor activity in these cancers by enhancing T cell-mediated immune responses.

In addition to cancer, Tamgiblimab Biosimilar is also being investigated as a potential treatment for autoimmune disorders, such as multiple sclerosis and rheumatoid arthritis. TIGIT has been found to play a role in the regulation of autoimmune responses, and by targeting this protein, Tamgiblimab Biosimilar has the potential to modulate these responses and provide therapeutic benefits.

Research Grade Tamgiblimab Biosimilar

Apart from its potential as a therapeutic agent, Tamgiblimab Biosimilar is also available in a research grade form. This grade is specifically designed for use in laboratory research and in vitro studies. Research grade Tamgiblimab Biosimilar is highly pure and has low endotoxin levels, making it suitable for use in various assays and experiments.

Conclusion

Tamgiblimab Biosimilar, also known as Anti-TIGIT mAb, is a novel monoclonal antibody that targets the TIGIT protein. It exerts its therapeutic effect by inhibiting the interaction between TIGIT and its ligands, leading to enhanced T cell function and anti-tumor immune responses. Tamgiblimab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various diseases. Its availability in a research grade form also makes it a valuable tool for laboratory research. Further studies and clinical trials are needed to fully understand the potential of Tamgiblimab Biosimilar as a therapeutic agent for cancer and autoimmune disorders.